No Data
No Data
Jiangsu Hengrui Pharmaceuticals (600276.SH) received the National Medical Products Administration's approval to issue the Approval Notice for Supplementary Application of Injection Paclitaxel (Albumin-bound).
On August 11th, Gelunhui announced that Jiangsu Hengrui Pharmaceutical Co., Ltd. has recently received the approval notice of supplementary drug application issued by the National Medical Products Administration (NMPA) for the injection of nab-paclitaxel (albumin-bound). The injection of nab-paclitaxel (albumin-bound) is an anti-microtubule drug developed by Abraxis Bioscience Inc. of the United States. It was first approved by the FDA for marketing in 2005 under the brand name Abraxane and is now marketed in the United States, the European Union, and Japan as a commodity.
Jiangsu Hengrui Pharmaceuticals (600276.SH): Currently not involved in the business of medical instruments related to human bones.
Jiangsu Hengrui Pharmaceuticals (600276.SH) stated on the interactive platform on August 9th that the company is an innovative international pharmaceutical enterprise dedicated to the research and development, production and promotion of high-quality drugs, focusing on the research and development of new drugs in areas such as anti-tumor, metabolic diseases, autoimmune diseases, respiratory system diseases, and nervous system diseases. Currently, it does not involve business in medical instruments related to the human skeleton.
Hengrui Pharmaceuticals Gets Nod to Trial Tumor Drug
Jiangsu Hengrui Pharmaceuticals (600276.SH): Nivolumab injection obtained a drug clinical trial approval letter.
On August 8th, Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary, Suzhou Shengdiya Biomedical Pharmaceutical Co., Ltd., received the National Medical Products Administration's approval and issuance of the "Drug Clinical Trial Approval Notice" for Fuanaxijuzhandankang injection. Clinical trials will be conducted in the near future. Fuanaxijuzhandankang injection is a recombinant humanized monoclonal antibody targeting human IL-17A independently developed by the company, intended to be used for the treatment of autoimmune diseases related to the IL-17 pathway.
Medicilon Y Hengrui Pharma Profundizan La Colaboración Estratégica
Medicilon Et Hengrui Pharma Renforcent Leur Collaboration Stratégique Pour Soutenir L'innovation Dans Les ADC, Les Petits Acides Nucléiques Et Les Médicaments CGT
No Data